➤ Topline results from Phase 3 studies for nAMD treatment ➤ Phase 2 trial of betamethasone treatment for cataract surgery pain and inflammation ➤ Fast Track designation given to therapy seeking to treat achromatopsia ➤ Topline data from Phase 1 trial of travoprost intracameral implant ➤ ASCRS Journal Club
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug ➤ Update from two Glaukos trials ➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making ➤ ASCRS events
➤ Success with first-in-human implant of new artificial cornea ➤ Launch of first longitudinal study for home OCT ➤ Enrollment complete for study evaluating treatment for Leber congenital amaurosis 10 ➤ Phase 1/2a trial for wet AMD treatment with suprachoroidal injection begins enrollment ➤ Fast Track designation issued for investigational dry AMD therapy
It’s important to address underlying conditions prior to cataract surgery, and dry eye is one such condition. Physicians must identify and treat it to ensure the tear film is optimized and measurements are correct.
There are several companies in the field of artificial irises. Kevin M. Miller, MD, and Sathish Srinivasan, MD, discussed the available products and important considerations when working with artificial irises.
With the COVID-19 pandemic temporarily closing practices around the country, many ophthalmologists had to figure out how to still communicate with and treat their patients. Several physicians commented on how the pandemic has affected their dry eye patient population and trends they have seen.
A retrospective study based on insurance claims data is giving real-world insights into prescribing/treatment patterns for two dry eye medications—cyclosporine ophthalmic emulsion (Restasis, Allergan) and lifitegrast ophthalmic solution (Xiidra, Novartis).1 In doing so, researchers can make inferences on adherence, discontinuation, and more.
When teens come into the clinic, it’s important to consider that they might have dry eye or meibomian gland disease. Investigators in a recent study found that among minors coming in for eye exams, 15% were experiencing dry eye discomfort and 9% had signs of meibomian gland dropout, according to lead investigator Anna Tichenor, PhD.1
The COVID-19 pandemic has affected all areas of medicine, including eye banking. While much more is known about SARS-CoV-2 and the illness it causes, there are still several unknowns that continue to be investigated as they pertain to the safety of donor tissue.
any practitioners are now reaching for Xiidra (lifitegrast, Shire, Lexington, Massachusetts) 5% for dry eye cases, but sometimes a patient may not initially be considered a success. Here’s what leading practitioners are doing to help more patients find respite with Xiidra.